{"id":"dsxs-topical-product","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Skin irritation"},{"rate":"5-10%","effect":"Allergic contact dermatitis"},{"rate":"1-5%","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL2108694","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Corticosteroids like DSXS work by inhibiting the production of inflammatory mediators, such as prostaglandins and leukotrienes, which contribute to the symptoms of inflammation and itching. By suppressing the immune system, DSXS reduces the body's natural response to allergens and irritants, providing relief from symptoms.","oneSentence":"DSXS topical product is a corticosteroid that reduces inflammation and itching by suppressing the immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:35:37.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seborrheic dermatitis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT02618759","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-08-28","conditions":"Plaque Psoriasis","enrollment":119},{"nctId":"NCT02933502","phase":"PHASE2","title":"Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-07-11","conditions":"Scalp Psoriasis","enrollment":3},{"nctId":"NCT02595073","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-09-04","conditions":"Atopic Dermatitis","enrollment":124},{"nctId":"NCT02932891","phase":"PHASE2","title":"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-08","conditions":"Atopic Dermatitis","enrollment":28},{"nctId":"NCT02595008","phase":"PHASE2","title":"Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-08-28","conditions":"Dermatitis, Atopic","enrollment":24},{"nctId":"NCT02932462","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-03","conditions":"Scalp Psoriasis","enrollment":373},{"nctId":"NCT02933866","phase":"PHASE3","title":"Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-03-11","conditions":"Scalp Psoriasis","enrollment":371},{"nctId":"NCT02933528","phase":"PHASE2","title":"Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-07-11","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT02932878","phase":"PHASE2","title":"An Open Label, Safety Study to Assess the Potential for Adrenal Suppression","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-09-02","conditions":"Plaque Psoriasis","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Active"],"phase":"phase_2","status":"active","brandName":"DSXS topical product","genericName":"DSXS topical product","companyName":"Sun Pharmaceutical Industries, Inc.","companyId":"sun-pharmaceutical-industries-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DSXS topical is a product used to treat conditions such as atopic dermatitis, plaque psoriasis, and scalp psoriasis, as indicated by ClinicalTrials.gov. The exact mechanism of DSXS topical is unknown, according to ChEMBL.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}